A golden age of asthma research

More than a decade ago, there was a widely held opinion among respiratory clinicians and researchers that asthma was, for the most part, solved and not worth investing intellectual or financial capital into research. There was certainly a small proportion of the asthma population (<10%) with severe refractory asthma, who merited attention [1]; but the vast majority of asthmatic patients were well served with the available treatment armamentarium of rapid onset bronchodilators (mainly short-acting inhaled β2-agonists (SABAs)), inhaled corticosteroids (ICS), or ICS and long-acting inhaled β2-agonist (LABA) combinations delivered from a single inhaler.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Editorials Source Type: research